Abstract 1201P
Background
Retrospective, single-institution study accessing the efficacy of TEMCAP regiment in pts. with advanced, unresectable progressive GEP-NET as a first or further lines after initial disease progression. Primary endpoint: progression-free survival (PFS), as initial with/without SST analogues previous therapy, PFS as second or further lines therapy using locally evaluation according to RECIST 1.1. Secondary goals: PFS in different subgroups and overall survival (OS).
Methods
54 pts with advanced unresectable, progressive GEP-NET. Mean age 58.0 (SD+/-12.4). All histological confirmed NETs: G1 n=10, G2 n=31, G3 n=13. Standard therapy approach using TEMCAP in all subjects. Disease status and treatment efficiency were evaluated according to localization of primary, initial vs. second or further line systemic therapy, bulky (>25% of liver volume) vs. not bulky liver disease, male vs. female, BMI ≤24 or BM I>24. Standard KM method used to assess PFS and OS for all subjects and in different subgroups. Cox regression model to assess any significant covariates of PFS and OS.
Results
Pancreatic (panNET) n=32, midgut n=8; hindgut n=7 and 7 pts with CUP. PFS for all group 8.0 months (IQR 5.0-15.0), OS from initial diagnosis of GEP-NET 56.8 months (IQR 25.3-96.5); panNET n=32 -PFS=8.0 months (IQR 5.0-16.1), non-pancreas (n=22) PFS=6.2 (IQR 4.0-10.0), n.s. Initial therapy with TEMCAP n=24- PFS=9.2 (6.0-15.0) vs. second or further therapy n=30, PFS=6.0 (IQR 4.1-9.9) n.s. Bulky liver disease (n=31) PFS=7.9 (IQR 5.0-10.0) v.s. non-bulky liver disease (n=23) PFS=7.4 (IQR 4.4-17.0) n.s. Male (n=20) PFS=9.0 (IQR 5.7-15.0), vs. female (n=34) PFS=6.5 (IQR 5.0-11.5), n.s. Median BMI >24.0 PFS=7.0 (IQR 5.0-10.9), vs BMI≤24 PFS=9.0 (IQR 9.0-15.0), n.s. Cox Regression model did not find any significant predictor of improvement in PFS. In Cox regression model of OS indicated that high grade NET (G3) had HR=2.92 (CI 1.17-17.2) of death.
Conclusions
TEMCAP in real world data seems to be a good option in advanced, progressive GEP-NET with PFS=8 months, independently from the primary site, sex, BMI, liver involvement and previous therapy. Overall potential benefits in OS is seen in NETG1 or G2, but not in G3 with HR=2,92.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13
1140P - Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Presenter: Emilie Gerard
Session: Poster session 13
1141P - Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Presenter: Elena Croce
Session: Poster session 13
1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Presenter: Marlies Wakkee
Session: Poster session 13
1143P - Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Presenter: Daniela Esposito
Session: Poster session 13
1144P - High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
Presenter: Rahul Ladwa
Session: Poster session 13
1145P - Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Presenter: Juergen Becker
Session: Poster session 13
1146P - Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
Presenter: Giovanni Grignani
Session: Poster session 13
1148P - Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Presenter: Astrid Blom Fily
Session: Poster session 13